News & Views | Published:

PARP inhibitors: a treatment option for AML?

Nature Medicine volume 21, pages 13931394 (2015) | Download Citation

A new study provides a rationale for the use of poly (ADP-ribose) polymerase (PARP) inhibitors to trigger irreparable DNA damage as a therapeutic approach in acute myeloid leukemia (AML). It also provides support for combining PARP inhibitors with agents that reduce HOXA9 protein levels.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. N. Engl. J. Med. 369, 111–121 (2013).

  2. 2.

    et al. Nature 456, 66–72 (2008).

  3. 3.

    , & Nat. Med. 21, 1481–1490 (2015).

  4. 4.

    et al. N. Engl. J. Med. 373, 1697–1708 (2015).

  5. 5.

    et al. Nature 514, 107–111 (2014).

  6. 6.

    et al. Blood 113, 2375–2385 (2009).

  7. 7.

    et al. Cancer Res. 75, 1838–1845 (2015).

Download references

Author information

Affiliations

  1. Lan Wang, Pierre-Jacques Hamard and Stephen D. Nimer are at the Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.

    • Lan Wang
    • , Pierre-Jacques Hamard
    •  & Stephen D Nimer

Authors

  1. Search for Lan Wang in:

  2. Search for Pierre-Jacques Hamard in:

  3. Search for Stephen D Nimer in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Stephen D Nimer.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm.4007

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing